In vivo quantification of amyloid burden in TTR-related cardiac amyloidosis
| Autor: | Christoph Röcken, Felix M. Mottaghy, Mathias Burgmaier, Sebastian Reith, Florian Kahles, Svetlana Kintsler, Ruth Knüchel, Sandra Hamada, Alexander Marco Kollikowski, Nikolaus Marx |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
biology medicine.diagnostic_test Amyloid business.industry Amyloidosis Cardiomyopathy General Medicine 030204 cardiovascular system & hematology medicine.disease 030218 nuclear medicine & medical imaging 03 medical and health sciences Transthyretin 0302 clinical medicine Cardiac amyloidosis In vivo Cardiac magnetic resonance imaging Biopsy biology.protein Medicine Radiology business |
| Zdroj: | Intractable & Rare Diseases Research. 6:291-294 |
| ISSN: | 2186-361X 2186-3644 |
| DOI: | 10.5582/irdr.2017.01065 |
| Popis: | Cardiac transthyretin-related (ATTR) amyloidosis is a severe cardiomyopathy for which therapeutic approaches are currently under development. Because non-invasive imaging techniques such as cardiac magnetic resonance imaging and echocardiography are non-specific, the diagnosis of ATTR amyloidosis is still based on myocardial biopsy. Thus, diagnosis of ATTR amyloidosis is difficult in patients refusing myocardial biopsy. Furthermore, myocardial biopsy does not allow 3D-mapping and quantification of myocardial ATTR amyloid. In this report we describe a 99mTc-DPD-based molecular imaging technique for non-invasive single-step diagnosis, three-dimensional mapping and semiquantification of cardiac ATTR amyloidosis in a patient with suspected amyloid heart disease who initially rejected myocardial biopsy. This report underlines the clinical value of SPECT-based nuclear medicine imaging to enable non-invasive diagnosis of cardiac ATTR amyloidosis, particularly in patients rejecting biopsy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|